The latest biotech news

News and Trends 5 Dec 2016

Another Pharma sloughs off Small Molecules to focus on Biologics

BI has taken an axe to its small molecule discovery program in order to focus on immuno-oncology in the latest farewell to old-school chemical drugs. Over 90% of the drugs on the market today are small molecules, but the bell has been tolling for these therapies for some time now as biopharma is increasingly focused […]

December 5, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 5 Dec 2016

Video: Chatting with Immunocore about the Potential of Immuno-oncology

At Refresh in Paris, I had the opportunity to ask Eva-Lotta Allan,CBO of one of Europe’s hottest companies, Immunocore, some pointed questions. Immunocore is famous as one of the biggest biotech successes in Europe: the company raised the largest round ever on the continent (€300M!), built a solid technological platform and recruited top talents to manage […]

December 5, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 5 Dec 2016

Rethinking Bioplastics: Future Directions in the Industry

Where are bioplastics going? Last week, 300 experts came together in Berlin to “rethink Bioplastics” and their role in the much-hailed circular economy. The diversity of speakers and exhibitors at the 11th edition of the European Bioplastics Conference offers, in itself, an overview of the different fields and players that make up the bioplastics industry. […]

December 5, 2016 - 6 minutesmins - By Denise Neves Gameiro

sloth crossing the road Scenic Shutterbug fi

News and Trends 2 Dec 2016

Stories We Didn’t Cover: MDMA in Phase III, Another Death for Carmat

Try as we might, we can’t cover all the biotech news out there. During the week, we only pick the top stories to keep you informed but not waste your time. Here’s a roundup of news that didn’t make the cut this week. Sanofi has acquired Warp Drive Bio’s antibiotics program, which was born out of […]

December 2, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 2 Dec 2016

Better than ADCs? AstraZeneca bids for Bicyclic Peptides

AstraZeneca has signed a deal with Bicycle Therapeutics that could exceed €1B. The foundation is bicyclic peptides, which combine the best of antibodies and small molecules. Could Bicycle Drug Conjugates (BDCs) outperform ADCs? Bicycle Therapeutics is a company in Cambridge founded by one of the top biotech leaders in the UK’s golden triangle. Its unique technology […]

December 2, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 12 01 at 3.06.48 PM e1480601295300

News and Trends 2 Dec 2016

Mind, Mood and Microbes: Harnessing the Power of Probiotics

The canals of Amsterdam have attracted us this week to the capital of the Netherlands, where Winclove Probiotics has been working for more than 20 years in targeting the human microbiome. This field is now resurging, with research pointing to a close link between gut bacteria and human health. City: Amsterdam, the Netherlands Founded: 1991 Employees: 50+ Financial […]

December 2, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 1 Dec 2016

Evotec gets hold of CRISPR in a new Partnership with Merck

Evotec teamed up with Merck to boost its drug discovery services with CRISPR, entering the battlefield for the patent behind the discovery of the century. Apart from being a pioneer in the translation of research from academia to the clinic, Evotec is a successful CRO with top-level partners including Bayer, Roche, Sanofi, Boehringer Ingelheim and Takeda. The German company is […]

December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Dec 2016

Spain joins the Antibody-Drug Conjugate Bandwagon to fight Cancer

PharmaMar announced positive preclinical results for an ADC candidate, showing that the traditional chemistry-based pharma companies are shifting towards the new generation of biologicals. PharmaMar is an oncology pharma in Madrid mining a vast source for drug discovery: marine organisms. The company is now pivoting to a more innovative technology with the announcement of positive […]

December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Dec 2016

7 European Institutions in the Largest Cancer Bioinformatics Collaboration

Europe’s best companies using bioinformatics to tackle cancer will take part in a huge collaboration aimed at developing personalized cancer vaccines. Three biotech companies and four research institutions from Europe are taking part in the Tumor Neoantigen Selection Alliance (TESLA). This is one of the biggest oncology collaborations ever, consisting of 30 organizations and led by […]

December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Dec 2016

UPDATE: The HIV Frontier starts Phase III Vaccine trials in South Africa

Update (01/12/2016): The HVTN 702 trial has been started, making it the first HIV vaccine efficacy study in 7 years worldwide. Results are expected in late 2020. Originally published 25/07/2016 A Phase IIb/III trial for an experimental HIV vaccine just started in South Africa. The therapy, co-funded by the NIH and the Gates Foundation, is a combination […]

December 1, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 1 Dec 2016

It’s World AIDS Day, is Biotech close to an HIV Cure?

Biotech is working hard on developing an HIV cure, as well as fast diagnostics and vaccines. For those living with the disease, 2016 seems to be bringing new hope from the hands of science. Today, the 1st of December, is World AIDS Day. More than 36 million people live with HIV and 1 million died last year. The […]

December 1, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Nov 2016

FDA and EMA review the First Therapy for a Deadly Skin Cancer

Merck and Pfizer have been granted priority review by the FDA for the first treatment dealing with one of the most aggressive forms of skin cancer. The FDA has accepted Merck and Pfizer‘s market application for avelumab in metastatic Merkel cell carcinoma (MCC) with priority review. Just a month ago, the EMA also accepted their application. If […]

November 30, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Another Pharma sloughs off Small Molecules to focus on Biologics

Video: Chatting with Immunocore about the Potential of Immuno-oncology

Rethinking Bioplastics: Future Directions in the Industry

Stories We Didn’t Cover: MDMA in Phase III, Another Death for Carmat

Better than ADCs? AstraZeneca bids for Bicyclic Peptides

Mind, Mood and Microbes: Harnessing the Power of Probiotics

Evotec gets hold of CRISPR in a new Partnership with Merck

Spain joins the Antibody-Drug Conjugate Bandwagon to fight Cancer

7 European Institutions in the Largest Cancer Bioinformatics Collaboration

UPDATE: The HIV Frontier starts Phase III Vaccine trials in South Africa

It’s World AIDS Day, is Biotech close to an HIV Cure?

FDA and EMA review the First Therapy for a Deadly Skin Cancer

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!